Trial Profile
"Evaluation of the safety and effect of treatment with intranasal NeuroEPO in patients with type 2 Spinocerebellar Ataxia"
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- Acronyms NeuroEPO-Ataxia
- 23 May 2022 Results published in the Movement Disorders
- 21 Jan 2016 New trial record